Pilot Study of INCB081776 Together With Palliative Radiation and Anti-PD-1 Checkpoint Blockade With Pembrolizumab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).

This document provides information about a clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC). The trial involves the use of a combination of drugs (INCB081776 and Pembrolizumab) and radiation therapy. The study aims to recruit 12 participants and is estimated to be completed by August 2026. Eligibility criteria include having incurable HNSCC, measurable disease, and willingness to provide research biopsies. The trial is being conducted by the University of Wisconsin, Madison, in collaboration with the National Institute of Dental and Craniofacial Research. [Extracted from the article]